Table 1 Correlation between ITGAV expression and clinicopathological features.
From: Pan-cancer landscape of ITGAV and its potential role in gastric cancer
Parameters | Total (n = 110) | ITGAV protein expression | P value | |
|---|---|---|---|---|
Positive (n = 69) | Negative (n = 41) | |||
Age, years | ||||
≤ 60 | 53 | 33 | 20 | 0.923 |
> 60 | 57 | 36 | 21 | |
Gender | ||||
Male | 76 | 51 | 25 | 0.156 |
Female | 34 | 18 | 16 | |
Tumor size | ||||
≤ 5 cm | 63 | 40 | 23 | 0.919 |
> 5 cm | 47 | 29 | 18 | |
Differentiation | ||||
Well/moderate | 28 | 19 | 9 | 0.516 |
Poor/undifferentiation | 82 | 50 | 32 | |
Serosal invasion | ||||
Negative | 32 | 15 | 17 | 0.028 |
Positive | 78 | 54 | 24 | |
Lymph node metastasis | ||||
Negative | 37 | 10 | 27 | 0.000 |
Positive | 73 | 59 | 14 | |
pTNM stage | ||||
I-II | 35 | 16 | 19 | 0.012 |
III | 75 | 53 | 22 | |
